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 The purpose of this study was to investigate the development of chemotherapeutic 
resistance to paclitaxel in ovarian cancer cells after treatment with drugs that are substrates for P-
glycoprotein (PGP). A core concept of this experiment was to identify if PGP substrate drugs 
could also act as PGP inducers after prolonged treatment in SKOV-3 ovarian cancer cells. In 
order to test this, SKOV-3 cells were exposed to either fexofenadine, a PGP substrate used as an 
antihistamine, or the chemotherapeutic drug vinblastine. After 42 days of drug treatment, ABCB1 
gene expression was measured by qRT-PCR. Analysis of ABCB1 expression in treated cells 
revealed that fexofenadine was unable to significantly induce gene expression in SKOV-3 cells. 
Although some cells treated with vinblastine did exhibit some significant increases in ABCB1 
expression, vinblastine exposure overall could not reliably induce ABCB1 gene expression within 
SKOV-3 cells. After testing for PGP induction, treated cells were exposed paclitaxel and tested 
for cell survivability. The results indicated that cells with induced PGP exhibited reduced 
survivability against paclitaxel exposure.  
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Ovarian Cancer affects around 204,000 women a year all over the world and of those it is 
responsible for nearly 125,000 deaths. In the United States alone approximately 22,000 new 
cases manifest each year leading to more deaths than any other type of female reproductive 
cancer (12). These statistics are bolstered by the fact that nearly 70% of ovarian cancers are 
diagnosed at an advanced stage the result being that women with this diagnosis can at best only 
expect to survive for another 5 years. This poor diagnosis has led to this form of cancer being 
known as a ‘silent killer’ as it shows very few symptoms until after it metastasizes within the 
peritoneal cavity of the patient (2). Similar to other cancers which are often detected in advanced 
stages, cancerous cells often develop drug resistance which renders numerous chemotherapeutics 
largely ineffective against the disease and forces doctors to treat patients with other medications 
that may prove less effective (2).  
The development of this resistance within cancerous tissues to chemotherapeutic drugs is 
known as multidrug resistance (MDR) and it represents a grave threat to the efficiency of most 
widely used chemotherapy agents (15). It was discovered nearly 40 years that MDR played a 
vital evolutionary role in an animal’s defense against environmental toxins by mobilizing cellular 
efflux pumps present on the cell membrane to pump out invading toxic substances (19). The 
overexpression of these pumps in cancerous cells however is what causes this normally 
advantageous mechanism to work against the greater good of a cancerous body essentially 
rendering many chemotherapeutic drugs ineffective. A significant mechanism which confers 
resistance to cancer is their active removal of the chemotherapeutic drugs from the cancer cells 
by drug transporters in the ATP Binding Cassette (ABC) family. Those that have been found to 
be associated with MDR include P-glycoprotein (PGP), Multidrug Resistance Proteins (MRPs), 
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and Breast Cancer Resistance Protein (BCRP) but this proposed project will focus specifically on 
the role of PGP in drug resistance (15).  
PGP Is a 170-kDA ABC transporter comprised of 1280 amino acids which acts as an 
ATP energy dependent efflux pump. It is encoded by the ABCB1 gene, alternatively known as 
MDR1, which is present on chromosome 7q21 (3).  It has 2 symmetrical amino and carboxyl 
halves known as cassettes which consist of 6 transmembrane domains (TMDs) each. These 
TMDs are the channels by which cells utilize these binding cassettes to power the expulsion of 
cytotoxic drugs out of the cell to by hydrolyzing ATP. This action effectively reduces 
intracellular drug concentrations. The ABCs are linked together by a polypeptide loop of about 
80 amino acids with an ATP-binding motif (3). There are 2 ATP binding domains (alternatively 
known as Nucleotide Binding Domains) which power PGP function and they are both located in 
the cytoplasm and function to transfer energy to transport substrates across the membranes. Both 
NBDS are essential for the ability to bind drugs to the binding sites located on the extracellular 
surface of the protein (18). These drug binding sites are known to be quite mobile and likely 
adjust based on different drugs employing a mechanism known as ‘substrate-induced fitting’ (1). 
This flexibility is what allows them to be involved in so many processes of the body and to have 
effects against such a diverse array of drugs with dissimilar structures (3).  
PGP is expressed in the lining of the gastrointestinal tract and endothelial cells of the 
blood brain barrier. It is also present in many other tissues including the bile duct, adrenal gland, 
kidney tubules, small intestine, pancreatic duct, heart, lungs, spleen, certain skeletal muscles, and 
the ovarian blood barrier (4). PGP functions by pumping the drugs out of the cells after oral 
ingestion due to its station in the apical membranes of enterocytes of the intestine. Then when 
the drugs enter systemic circulation, PGP aids in the removal of these drugs through urine and 
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bile due to its presence on hepatocytes and the apical surface of the kidney’s tubular cells (4). 
PGP also appears to regulate hormone distribution and may regulate cell differentiation, 
proliferation, immune responses and programmed cell death otherwise known as apoptosis (1).  
In healthy cells, P-glycoprotein mediated drug efflux is believed to occur based on one of 
three possible mechanisms. The first is known as the classical pore pump model and it has PGP 
forming a hydrophilic tunnel by which recognized substrates are exchanged from the cytosol into 
the extracellular media. The second method is called the hydrophobic vacuum cleaner model and 
it has PGP binding directly with hydrophobic substrates within the inner side of the plasma 
membrane and then expelling them out of the cell upon identifying them as xenobiotic in nature 
The substrates are held between the internal aqueous compartment and the inner membrane 
surface of the cell before PGP makes contact which then results in conformational alterations to 
the transporter itself to remove the substrate to the external medium (5).  The third and final 
model is the most accepted of the three, it is called the flippase model and it has PGP 
intercepting the drug as it travels through the lipid membrane and flipping the drug from the 
inner leaflet (the inner side of the plasma membrane) toward the outer leaflet (the outer side of 
the plasma membrane) against the concentration gradient via ATP hydrolysis (18). 
There are four primary mechanisms of drug resistance. The first is enhanced efflux of a 
drug by proteins such as the aforementioned ABC family of efflux pumps including P-
glycoprotein. Other efflux transporters include the Breast Cancer Resistance Protein and the 
Multidrug Resistance Proteins 1-3. The second method of drug resistance is through the 
modulation of drug-induced apoptotic progression in which PGP may also be involved. The third 
method involves the development of changes in the cell’s ability fix DNA damage due to genetic 
variance in the coding for repair proteins of drug-targeted molecules (1).  The fourth and final 
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method is the acceleration of drug metabolism by enzymes such as glutathione S-transferase or 
GST. It is generally accepted that MDR is most often the result of multiple of the above methods 
occurring together but the most prevalent method associated with multidrug resistance is the 
enhanced efflux by ABC family pumps (1). 
In addition to the methods above, there are some unique chemotherapeutic drugs which 
cannot be transported by PGP whose use can result in the manifestation of the MDR phenotype 
through other more unconventional means. In the unique case of cisplatin-induced PGP 
expression, the drug can act as a ligand to the xenobiotic detecting pregnane X receptor (PXR) 
which has been shown to have a degree of transcriptional control over PGP (1,16). In this way, 
the development of drug resistance to cisplatin in cancer cells is an indirect method of resistance 
to PGP rather than a direct link to the pump itself (6, 15). This PXR-mediated PGP 
overexpression has further been associated with resistance to both paclitaxel and vinblastine in 
LS180 colon cancer cells (9). 
In cancerous cells, drug resistance conferred by the expulsion of drugs from the cells by 
ABC transporters such as PGP, BCRP, and numerous other MRPs. The overexpression of PGP 
can greatly diminish the intracellular retention of these therapeutic agents (15). In recurrent 
ovarian cancer cases the changes in ABCB1 expression is assessed as PGP has been proposed as 
a viable biomarker for drug resistance in cancer patients (22). Further, induced PGP expression 
has been detected in tumors exposed common drugs which act as immunosuppressants, 
antihypertensives, antihistamines, antimicrobials, and anti-inflammatories (16). Due to the high 
diversity of drugs that are recognized and transported by PGP however there are also many 
therapeutic drugs which are known to act as both PGP substrates and inhibitors which include 
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calcium channel agonists, calmodulin antagonists, local anesthetics, steroids, protein-kinase 
inhibitors, detergents, and other immunosuppressive agents (1). 
The most efficacious chemotherapeutic drugs used in the treatment of ovarian cancer 
today are cisplatin, its analogue carboplatin, and paclitaxel which all are commonly administered 
together in a treatment regimen (12). An issue with these treatments however is that resistance 
may develop to these drugs, ultimately leading to treatment failure. While cisplatin can develop 
resistance using the unique PXR-related methodology mentioned earlier, cancer cell resistance to 
paclitaxel has primarily been found to be mediated through ABC proteins such as PGP (15). 
Another anti-cancer chemotherapeutic drug of interest is vinblastine which is a vinca alkaloid 
used as a cytotoxic agent to treat patients with lymphoma, leukemia, ovarian cancer, breast 
cancer, colorectal cancer, as well as other types of solid tumors. Like paclitaxel, vinblastine is a 
known PGP substrate which has been shown to be capable of inducing PGP (9). The common 
antihistamine fexofenadine (commercially known as Allegra) is also a known PGP substrate 
which also may be capable of PGP induction (personal communication, Dr. Christopher Farrell).  
In recent years however, research has been done using cancer cell lines to identify drugs 
which can act as substrates for PGP. These medications that are commonly used by patients for 
co-morbidities may cause an induction of PGP expression in cancer cells, possibly conferring 
resistance to chemotherapeutics used to treat those tumors. The purpose of this experiment was 
to induce the expression of PGP in the ovarian cancer cell line SKOV-3 using the PGP substrates 
fexofenadine and vinblastine and then to determine if the PGP-induced SKOV-3 cells display 
primary drug resistance to paclitaxel. We hypothesize that when ovarian cancer cells are exposed 
to these PGP-substrate drugs the cancer cells will begin to overexpress the P-glycoprotein 
transporter and will then display drug resistance. 
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Materials and Methods 
Reagents  
The drug vinblastine acted as a positive control and fexofenadine served as the test PGP 
inducer, both were purchased from Sigma Aldrich. The chemotherapeutic paclitaxel used to 
determine drug resistance in PGP expressed cancer cells was purchased from Sigma Aldrich. The 
SKOV-3 human ovarian cancer cell line and RPMI 1640 medium used to culture them were 
purchased from ThermoFisher Scientific along with 10% Fetal Bovine Serum. When sub-
culturing cells, Trypsin 0.53 mM EDTA solution was purchased from ATCC and used to 
disperse cell layers before the new medium is added. In preparation for performing quantitative 
real-time PCR (qRTPCR), the Purelink RNA Mini kit was purchased from Thermofisher for 
RNA isolation along with the SuperScript II Reverse Transcriptase kit for cDNA synthesis from 
Invitrogen. Taqman Advanced Master Mix and custom assays for HPRT1 and ABCB1 were 
purchased from ThermoFisher Scientific. Additionally, dNTPs and random hexamer primers for 
expression profiling were purchased from Invitrogen. To determine cell viability the PrestoBlue 
Cell Viability Assay kit was purchased from ThermoFisher Scientific.  
Cell Culture 
 The SKOV-3 cells were maintained as monolayers in complete RPMI 1640 medium with 
10% fetal bovine serum. SKOV-3 cells were grown for three passages before beginning any drug 
exposures. After the third passage, all cells were given at least seven days of growth in the 
incubator with media changeout at least twice per week depending on cellular health. The cells 
were contained in either T.75 flasks or 75mm petri dishes and stored in a 151L CO2 incubator set 
to 5% and 37ºC.  
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Dose Response Curve 
 To determine drug concentrations of fexofenadine and vinblastine for use in the induction 
studies which could maintain cellular health, a dose response curve was performed using 
separate groups of SKOV-3 cells. Each group was treated with one of three concentrations of 
either vinblastine or fexofenadine. Vinblastine and Fexofenadine were solubilized in DMSO first 
and then diluted into water. Vinblastine was prepared at concentrations of 2nM, 10nM and 30nM 
with in a final DMSO concentrations of 4.732e-7%, 1.23e-5%, and 0.0001% respectively. 
Fexofenadine was prepared at concentrations of 25μM, 75μM, and 125μM with in a final DMSO 
concentrations of 0.005%, 0.68%, and 1.3% respectively. The cells were then cultured for a week 
with media changes on day 3 and 5. These drug concentrations were based on previous research 
in PGP induction with the same drugs and through email correspondence with Dr. Christopher 
Farrell (7, 8). Treated cells then were harvested and assessed for cell viability using the 
PrestoBlue assay. The highest concentration which maintained cellular viability for each drug 
was selected to continue on with the induction study. Cellular viability was based on the visual 
health of the populations as determined by cell confluence and number of dead cells counted in 
the media. Results from PrestoBlue experiment was analyzed using an Infinite M200 Pro-Tecan 
plate reader at the University of the Incarnate Word. 
PGP Induction  
 Based on results from the dose response curve the 75μM fexofenadine and 2nM 
vinblastine concentrations were chosen for the PGP induction studies. The DMSO vehicle 
controls were prepared at a concentration of 0.68%, this matches the 75μM fexofenadine 
exposure as this is highest DMSO content of all treatments. The induction study was repeated 
three times with each exposing SKOV-3 cells to drug conditions for 42 days. Within each study 
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the drug exposures were performed in triplicate. The intent was to have media changeout 
occurring every three days and RNA isolation every seven days. Because of differences in cell 
growth rate due to drug exposure however some timepoints were moved to allow for additional 
days of growth. Throughout all 3 studies untreated control cells were maintained with RNA 
isolation taken at the beginning and end of each induction study.  
qRTPCR 
After each induction study had concluded the isolated RNA collected from the cells was 
analyzed for signs of PGP induction utilizing qRT-PCR. The isolated mRNA was used to 
synthesize cDNA using the Superscript II Reverse Transcriptase kit from Invitrogen. Expression 
of ABCB1 was evaluated with customized Taqman Gene Expression Assays purchased from 
Thermofisher Scientific for ABCB1 (Hs00184500_m1) and the housekeeping gene HPRT1 
(Hs01003267_m1). Expression was detected using fluorescent probes for ABCB1 and HPRT1 
with a Bio-Rad C1000 Touch Thermocycler. The CT values provided by the thermocycler were 
then used the analyze the ABCB1 gene expression relative to the expression of the housekeeping 
gene HPRT1, this is known as the delta cycle threshold (ΔCT) value. The ΔCT values for each 
exposure was additionally compared to the values from the untreated controls. 
Delta Ct = Ct gene test – Ct endogenous control 
Paclitaxel Resistance  
 After each induction study concluded the treated SKOV-3 cells were exposed to 
paclitaxel to assess if PGP induction could confer resistance to the chemotherapeutic drug. 
Paclitaxel was solubilized in DMSO and then diluted into water. The paclitaxel concentrations 
for these experiments were 0.1µM and 1µM with in a final DMSO concentrations of 0.0016% 
and 0.0169% respectively. SKOV-3 cells were plated onto a 96-well plate and exposed to RPMI 
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media with either 0.1µM and 1µM paclitaxel for 24 hours. After this period the cells were then 
tested for cell viability using the PrestoBlue Cell Viability Assay. Results from PrestoBlue 
experiment was analyzed using an Infinite M200 Pro-Tecan plate reader at the University of the 
Incarnate Word. This experiment was only performed at the conclusion of the second and third 
PGP induction studies. 
Data Analysis and Statistics 
 The ΔCT values produced by the PCR machine were used to examine PGP expression for 
each study. At each timepoint, results from every exposure group was analyzed using a Student’s 
t-test as compared to the untreated controls collected at the start of each study. Statistical analysis 
was performed in SPSS version 24 and Microsoft Excel 2016. Cell viability data gathered using 
the PrestoBlue assay after paclitaxel exposure was evaluated by comparing results to the 
untreated control cells. 
Results 
ABCB1 Expression in Treated SKOV-3 Cells 
The expression level of ABCB1 was investigated to determine if treatment with 75µM 
fexofenadine or 2nM vinblastine could induce ABCB1 expression in SKOV-3 cells. The ∆Ct 
values normalizes the expression of ABCB1 to that of the housekeeping gene HPRT1. 
Significance for each ∆Ct value was determined through comparison against the day 0 untreated 
controls. All of the 0.68% DMSO vehicle control samples exhibited a statistically significant 
decrease in ABCB1 expression with samples collected from day two and four showing the 
sharpest decline (p > 0.001) (Figure 1). The remainder of the DMSO samples displayed a 
statistically significant decrease of (p > 0.05) in ABCB1 expression. Samples treated with 75µM 
fexofenadine were observed to have a statistically significant decrease in ABCB1 expression on 
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day 14 (p > 0.001) and day 31 (p > 0.05). None of the fexofenadine treated samples exhibited 
any significant signs of ABCB1 induction (Figure 1). The 2nM vinblastine treated cells displayed 
no significant increase in ABCB1 expression throughout the study (Figure 1). 
 
Figure 1. Expression analysis of ABCB1 in drug treated SKOV-3 cells from the first induction 
study as measured by qRT-PCR. Chart utilizes ∆Ct values which compare ABCB1 expression to 
that of the endogenous control gene HPRT1. Values were compared with the day 0 untreated 
cells to determine significance and were considered significant at *p < 0.05, **p < 0.01 and ***p 
< 0.001. 
 
The second induction study was carried out using the same treatments as previously 
described with the addition of untreated cells which ran concurrently to the other treatments and 
had RNA isolated on day zero and day 56. The cells from the DMSO vehicle controls were 
observed to have a significantly significant decrease (p > 0.05) in PGP expression starting from 
day 15 until the end of the test period (Figure 2). The 75µM fexofenadine treated samples from 
day four exhibited statistically significant decrease (p > 0.05) in PGP expression. All remaining 
samples treated with fexofenadine did not indicate any significant signs of ABCB1 induction 
(Figure 2). The 2nM vinblastine treated cells displayed a statistically significant decrease (p > 
0.05) in ABCB1 expression in samples starting from day 15 until the end of the test period 
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(Figure 2). The vinblastine treated cells displayed ABCB1 expression levels beneath that of the 
other treatments for the duration of the study. 
  
Figure 2. Expression analysis of ABCB1 in drug treated SKOV-3 cells from the second 
induction study as measured by qRT-PCR. Chart utilizes ∆Ct values which compare ABCB1 
expression to that of the endogenous control gene HPRT1. Values were compared with the day 0 
untreated cells to determine significance and were considered significant at *p < 0.05, **p < 0.01 
and ***p < 0.001. 
 
 The third induction study utilized the same drug treatments as the previous studies and 
maintained a population of untreated control cells which had RNA isolated on day zero and 42. 
On day 42 of the study the DMSO vehicle samples displayed a statistically significant decrease 
(p > 0.01) in ABCB1 expression (Figure 3). The 75µM fexofenadine treated cells were observed 
to statistically significantly decrease (p > 0.01) in samples collected from day 21 (Figure 3). 
Additionally, fexofenadine treated samples from day 42 displayed a statistically significant 
decrease (p > 0.001) in ABCB1 expression.  Both the DMSO vehicle and 75µM fexofenadine 
treated cells overall maintained a steady decrease in ABCB1 expression throughout the study. 
The 2nM vinblastine treated cells exhibited a statistically significant increase (p > 0.05) in 
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ABCB1 expression on samples from day 14. Vinblastine treated cells also displayed a significant 
decrease (p > 0.05) in ABCB1 on day 42 (Figure 3). 
  
Figure 3. Expression analysis of ABCB1 in drug treated SKOV-3 cells from the third induction 
study as measured by qRT-PCR. Chart utilizes ∆Ct values which compare ABCB1 expression to 
that of the endogenous control gene HPRT1. Values were compared with the day 0 untreated 
cells to determine significance and were considered significant at *p < 0.05, **p < 0.01 and ***p 
< 0.001. 
 
Resistance to Paclitaxel in Treated SKOV-3 Cells as Determined by PrestoBlue Viability 
Assay 
 
 In order to assess if PGP induction could result in the development of drug resistance the 
treated SKOV-3 cells were then exposed to paclitaxel. After the SKOV-3 cells from the second 
induction study were treated for 42 days with each drug condition, they were removed from the 
fexofenadine or vinblastine exposure and then exposed one of two different concentrations of 
paclitaxel and tested for cell viability on Day 51. The charts below reflect the absorbance of 
PrestoBlue as compared to media only controls, groups with higher absorbance indicate superior 
survival against paclitaxel exposure. Based on the recommendation of the protocol provided by 
Thermofisher, cell viability was detected after 20 minutes of incubation. For the 0.1µM 
paclitaxel exposure experiment, the DMSO control and 2nM vinblastine treated cells overall 
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exhibited similar survival when compared to the untreated controls. The 75µM fexofenadine 
cells had the worst survival with absorbance nearly half of that of untreated controls (Figure 4a). 
For the 1µM paclitaxel exposure experiment, all groups exhibited lower survival than the 
previous 0.1µM exposure. The 2nM vinblastine treated samples showed the highest survival of 
all treatments (Figure 4b). The untreated control cells had the second-best survival falling just 
behind the vinblastine cells. Both the DMSO control and 75µM fexofenadine treated cells both 
displayed poor survivability when compared the vinblastine cells exposed to the same paclitaxel 
treatment (Figure 4b). 
 
Figure 4. Cell viability analysis of treated SKOV-3 cells after exposure to paclitaxel to ascertain 
presence of resistance to chemotherapeutic treatment. SKOV-3 cells from the second induction 
study (Day 51) were exposed to 2 different concentrations of paclitaxel and measured for cell 
viability after 20 minutes using PrestoBlue assay. The media corrected absorbance values were 
read at 570 nm and normalized to the 600 nm values. Cells exhibiting resistance to paclitaxel 
should have greater cell viability.  (a) Treated SKOV-3 cells exposed to 1µM of Paclitaxel. (b) 
Treated SKOV-3 cells exposed to 0.1µM of Paclitaxel. 
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 After the third induction study had concluded the cells were exposed to 0.1µM of 
paclitaxel the DMSO treated samples exhibited the greatest survival of all treatments. The 
untreated control and 75µM fexofenadine treated cells exposed to paclitaxel exhibited very 
similar survival with the untreated controls showing slightly greater absorbance. The 2nM 
vinblastine treated cells fared the worst with survival lower than any of the other treatments 
(Figure 5b). SKOV-3 cells exposed to 1µM of paclitaxel displayed similar trends to those found 
in the 0.1µM paclitaxel exposure. The greatest overall survival took place in the DMSO control 
samples (Figure 5b). The fexofenadine treated cell had very similar survival to the DMSO 
controls while the untreated control cells fared slightly worse. Cells treated with 2nM vinblastine 
had the worst survival with an absorbance less than half of any other treatment exposed to the 
same Paclitaxel dose (Figure 5b). 
Discussion 
 This study aimed to investigate the expression of ABCB1 in SKOV-3 ovarian cancer cells 
after treatment with vinblastine and fexofenadine, drugs identified as PGP substrates. Vinblastine 
is a powerful chemotherapeutic drug which has a documented history as a PGP inducer, and 
thus, it was selected as a positive control for this study (13, 16). Fexofenadine is an over-the-
counter antihistamine commonly used to relieve allergy symptoms that is also a known PGP 
substrate (16). Fexofenadine was chosen for this study because of the implications this drug 
could have for patients before a cancer diagnosis. If treatment with fexofenadine can alter 
ABCB1 expression and its associated regulatory mechanisms in cancer cells it could impact the 
efficacy of chemotherapeutic drugs like paclitaxel. PGP induction specifically has been 
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Figure 5. Cell viability analysis of treated SKOV-3 cells after exposure to paclitaxel to ascertain 
presence of resistance to chemotherapeutic treatment. SKOV-3 cells from the third induction 
study (Day 51) were exposed to 2 different concentrations of paclitaxel and measured for cell 
viability after 20 minutes using PrestoBlue assay. The media corrected absorbance values were 
read at 570 nm and normalized to the 600 nm values. Cells exhibiting resistance to paclitaxel 
should have greater cell viability.  (a) Treated SKOV-3 cells exposed to 1µM of Paclitaxel. (b) 
Treated SKOV-3 cells exposed to 0.1µM of paclitaxel. 
 
identified as the target of an ever-growing number of inquiries involving the development of 
drug resistance. While the resulting alterations in gene expression through drug exposure could 
be transient in nature when produced in a lab environment, the acquisition of drug resistance 
through ABC transporter expression remains a relevant concern with the clinical community (23, 
24). 
Across all three PGP induction studies performed in this experiment, both the 
fexofenadine and DMSO vehicle controls consistently did not induce significant ABCB1 
induction. Results from the second and the third studies further indicate that both the 
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fexofenadine and DMSO controls display ABCB1 levels beneath that of untreated cells. The 
consistently similar results displayed by these two groups could be due to the fact that both 
exposures had the same 0.068% DMSO content. The vehicle controls were calculated to have the 
same percentage of DMSO as was used to make the 75µM fexofenadine exposure. Despite the 
similarity between these results, the DMSO vehicle cells in all three induction studies 
consistently exhibited more change with an overall negative trend as each study proceeded. 
Although the final DMSO concentration in these samples was beneath the recommended 0.1%, it 
is possible that the DMSO content was still enough to cause the PGP expression in SKOV-3 cells 
to fall. As this same amount of DMSO was used to solubilize fexofenadine in this study, this 
could indicate that the potential induction effects of fexofenadine exposure could have been 
counteracted by the toxicity of the DMSO. This conclusion however would require further 
investigation to verify. 
The vinblastine treated cells from the first and third induction studies were the only 
exposures to demonstrate an increase in ABCB1 expression. In the case of the first study however 
the values were not significant. The only vinblastine treated cells which did exhibit a significant 
increase in ABCB1 expression was from the third induction on day 15. Subsequent samples from 
the third induction study actually began to show a decrease with ABCB1 expression dipping 
beneath the untreated controls by the final day of the experiment. This could be a result of the 
transient nature of drug-induced ABCB1 induction documented in a study by Miklos et al which 
utilized SW480 cells. In a study published in the Journal of the National Cancer Institute, 
researchers further designated vinblastine specifically as a chemotherapeutic additionally capable 
of inducing stable ABCB1 expression in K562 cells, but not within HL-60 leukemia cells (24). 
The diversity of results vinblastine exposure can have among different cell types could 
23 
contribute to answering why exactly vinblastine failed to act as a reliable positive control in this 
study. 
The results from the vinblastine treated cells in second induction study were very 
different than the other two studies as they displayed a notable decrease in ABCB1 expression 
which did not level out until the third week of the study on Day 21. Like the third study all drug 
treated cells had lower ABCB1 expression when compared to the untreated SKOV-3 cells. This 
downward trend in the early days of the study may be related to an incident which occurred on 
the 10th day of the study during which the incubator failed and was no longer supplying CO2. 
During the transfer to a functioning incubator the cells were outside of a controlled environment 
for more than five hours. When this occurred the first and second induction studies were both 
running concurrently so the incubator had flasks with cells from both studies. The reason 
however that one does not see the possible implications of this incident in the first study is 
because the second study was started two weeks after the first. By day 10, the cells from study 
two had only experienced three days of growth since their last passage. The cells from the first 
study on the other hand were on day 27 and had already experienced a full week of growth since 
their last passage. To compensate for this the cells from both studies were given extra time to 
grow in an incubator at a separate facility as both were unable to reach confluence on schedule. 
Although this may have had an adverse effect on the cellular growth rate and morphology it 
cannot be fully concluded that the downward expression of ABCB1 displayed was directly the 
caused by the incubator malfunction.  
After generating a best fit trendline for all of the ∆Ct values with each condition for all 
three studies, the slopes of each line were analyzed to see the overall trend of how each treatment 
affected the cells. Trendlines for DMSO and fexofenadine treated cells in all three studies were 
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negative, meaning that the drugs overall decreased the expression of ABCB1 in SKOV-3 cells. 
While extremely similar, these negative trends do not deviate far from ABCB1 expression in 
untreated cells on shown on day zero (Figure 6a, 6b, 6c). This indicates that DMSO and 
fexofenadine treatments did not induce significant change in our SKOV-3 cells after 42 days of 
exposure. Trendlines generated for the vinblastine treated cells exhibit a notable degree of 
difference from study to study with only the first study having a positive trend towards ABCB1 
induction (Figure 6a). Similar to the first study, the trendline for the vinblastine treated cells in 
the third study also stays above that of the DMSO control and fexofenadine cells (Figure 6c). 
The trendline generated from the second study however exhibits a noticeable negative slope 
when compared to both the other treatments in the same study and the other vinblastine 
treatments from the other studies (Figure 6b). This statistically significant (p < 0.05) decline in 
ABCB1 expression requires further exploration to properly explain. 
 
Figure 6a. Trendline expression analysis of ABCB1 in drug treated SKOV-3 cells from the first 
induction study as measured by qRT-PCR. Utilizes ∆Ct values to generate best fit trendlines to 
visualize overall effects of each treatment on ABCB1 expression. 
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Figure 6b. Trendline expression analysis of ABCB1 in drug treated SKOV-3 cells from the 
second induction study as measured by qRT-PCR. Utilizes ∆Ct values to generate best fit 
trendlines to visualize overall effects of each treatment on ABCB1 expression. 
 
 
Figure 6c. Trendline expression analysis of ABCB1 in drug treated SKOV-3 cells from the third 
induction study as measured by qRT-PCR. Utilizes ∆Ct values to generate best fit trendlines to 
visualize overall effects of each treatment on ABCB1 expression. 
 
In order to statistically examine the reproducibility of PCR results across the three 
induction studies, the confidence intervals were identified for the slopes of each treatment’s best 
fit trendline across all of the induction studies. Using a linear regression model, Appendix A 
shows the results of this analysis which was conducted in IBM SPSS (Statistical Package for the 
Social Sciences). If the slope of each trendline all fit into the same 95% confidence intervals, 
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then there is insufficient evidence to conclude that the slope of each line differs significantly. 
The slope lines for fexofenadine treated cells from study one and three do not differ 
significantly; thus, there is insufficient evidence to say that the results of these treatments differ 
in SKOV-3 cells. The slope line of the fexofenadine cells from the second induction study does 
somewhat overlap with that of the first, but not of the third study. This indicates that the cells 
between the second and third study do show significantly different results from their respective 
treatments. The slopes generated for DMSO-treated cells all overlap meaning that there is 
insufficient evidence to conclude that results of this exposure differed between the three studies 
for this treatment. Finally, the slopes generated from the trendlines in vinblastine treated cells 
overlapped in cells from study one and three. This indicates that the change in ABCB1 expression 
did not differ in a significant way between cells of those studies. The slope for vinblastine treated 
cells in study two, however, does differ significantly from the similarly exposed cells from either 
the first or third studies. This variance present in the results SKOV-3 cells indicates the need for 
further testing as to whether either substrate could reliably induce PGP in SKOV-3 cells. 
While the data was unable reliably demonstrate fexofenadine or vinblastine induced 
ABCB1 expression in our SKOV-3 cells, the idea of PGP substrate drugs possibly acting as 
inducers remains a query worth exploring. Across numerous cell types, the expression of ABCB1 
has been shown to play a role in the absorption and secretion of numerous anticancer drugs (10). 
The anticancer drug vinblastine’s association with ABCB1 expression especially seems 
noteworthy based on findings of studies which utilize other cell types. For example, a study 
performed by Harmsen et al. in 2010 utilized a LS180 colon cancer cell line to verify that 
anticancer drugs, such as paclitaxel and vinblastine could induce PXR-mediated PGP 
overexpression. (9). Another study which utilized human neural stem/precursor cells (hNSPCs) 
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found that treatment with vinblastine resulted in the drug-induced expression of ABCB1 (13). 
Using a SW840 colon cancer cell line with known ABCB1 overexpression, Miklos et al. 
attempted to verify the impact ABCB1 expression could have on resistance to the 
chemotherapeutic triapine, which itself is a substrate of PGP. While they concluded that triapine 
was only a weak substrate for PGP, they did interestingly find that treatment with triapine 
resulted in the upregulation of ABCB1 in their SW840 colon cancer cells. They concluded that 
this upregulation was due to the stress the cells underwent with exposure to triapine (23). 
Whether or not SKOV-3 cells could exhibit a comparable mechanism that could alter ABCB1 
expression when under similar pressure may be a topic worth further investigation. 
In addition to any ABCB1 gene expression effects, some of the drug treatments utilized in 
this study did have an observable effect on the morphology and health of the SKOV-3 cells. The 
normal untreated SKOV-3 cells, as well as those treated with 0.068% DMSO, had a ‘spiderlike’ 
structure that when plated with two million cells would reach confluence inside of a T-75 flask 
after seven days (Figure 7a, 7b). Using the official ATCC documentation on the cells as well as 
the untreated controls as a baseline for average SKOV-3 growth patterns, the 75µM fexofenadine 
treated cells appeared to display somewhat augmented growth. A T-75 flask of untreated cells 
generally was expected to be confluent within a week but fexofenadine treated cells often would 
reach confluence in as few as five days despite being initially plated with the same number of 
cells. While these flasks would of course yield much higher cell counts than the other treatments 
the morphology of the SKOV-3 cells would remain largely unchanged (Figure 7c). The 2nM 
vinblastine treated cells developed an irregular globular shape that would form clusters or islands 
of growth rather than spread out across the plate (Figure 7d). In addition to these new 
characteristics, the vinblastine treated cells often were in poor health and low confluence after 
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each week, sometimes requiring a higher plating density of cells to even make the required 
numbers of cells for each week of the experiment. While this obviously is tied to the potency of 
vinblastine as a chemotherapeutic agent the effect this more extreme environment could have 
resulted in innumerable changes on the gene expression of the SKOV-3 cells. The exact relation 
between the health of the cells, as indicated by higher cell counts or changes in their 
morphology, and the expression of ABCB1 remains unknown and requires further investigation. 
 
 
Figure 7. SKOV-3 cells imaged under each under each treatment after 5 days of growth within a 
CO2 incubator. (a) Untreated SKOV-3 cells. (b) 0.068% DMSO treated SKOV-3 cells. (c) 75µM 
fexofenadine treated SKOV-3 cells. (d) 2nM vinblastine treated SKOV-3 cells. 
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The second aim of this experiment was to identify if SKOV-3 cells with augmented 
ABCB1 expression would exhibit resistance to treatment with the chemotherapeutic drug 
paclitaxel, which itself is a PGP substrate. In the cells taken from the second induction study, 
there was a notable difference in the survivability between the cells of each paclitaxel exposure, 
with the primary commonality being that the fexofenadine treated cells proved most susceptible 
to the cytotoxic effects of the drug under both conditions. In the cells from the second study 
exposed to 1µM paclitaxel, the greatest survivability was found in vinblastine treated cells. The 
next greatest survivability to 1µM paclitaxel was in the untreated control cells followed by the 
fexofenadine and lastly the DMSO treated cells. The cells from the second study exposed to 
0.1µM displayed markedly different results from the 1µM cells with the untreated control cells 
showing the strongest survivability. The DMSO and vinblastine treated cells trail just behind the 
untreated cells with notable survival towards paclitaxel while the fexofenadine treated cells again 
fared the worst. Based on the expression analysis from these cells the DMSO and fexofenadine 
treated cells showed no significant signs of ABCB1 induction so it unlikely that their 
susceptibility to paclitaxel treatment was related to that factor. Furthermore, the untreated 
baseline cells in both experiments exhibited both higher levels of ABCB1 than all other 
treatments. While noteworthy these trends are hardly consistent as the ABCB1 expression in 
baseline cells is not significantly induced. The ABCB1 expression in the vinblastine treated cells, 
which fared best against the 1µM paclitaxel exposure, additionally displayed greatly reduced 
gene expression which taken altogether indicates the need for further testing. 
In cells taken from the third induction study, the untreated, DMSO, and fexofenadine 
exposed cells all exhibited similar survivability for both concentrations of paclitaxel. In all of 
these samples, the cells exposed to the higher 1µM dose resulted in lower survivability across all 
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treatments than the cells exposed to the lower 0.1µM dose. The greatest survivability was 
displayed in DMSO samples, but since these cells showed very little difference in ABCB1 
expression to either the untreated controls, or the fexofenadine treated cells, the exact reason for 
this is unknown. By large margin the weakest survivability was found in vinblastine treated cells 
for both paclitaxel concentrations which noticeably varied from all other treatment types. One 
possible reason for this greatly diminished survivability may be due to the low yield and poor 
health of the vinblastine treated cells on day 49 of their treatment before they were exposed to 
paclitaxel. The diminished survival of the vinblastine treated cells towards paclitaxel treatment 
could be linked to the high toxicity of vinblastine which already had done considerable damage 
to the SKOV-3 population. Additionally, the visible health of the untreated, DMSO, and 
fexofenadine treated cells were all relatively at the same. Whether the relative health of the cells 
prior to exposure to paclitaxel could be the cause of this variance, however, will require further 
investigation to verify as the ABCB1 levels of the cells in each treatment by that time cannot be 
verified and thus true causality cannot be assumed. 
Altogether, the data from our paclitaxel exposures appears to illustrate an association 
between SKOV-3 cells with reduced ABCB1 expression and a degree of paclitaxel resistance as 
augmented survivability would indicate reduced sensitivity to the drug’s cytotoxic effects. This 
stands in opposition to established and well-described research which indicates that induction of 
ABCB1 expression is a viable mechanism for development of resistance to drugs such as 
paclitaxel (9, 21, 22). While there are various differing factors which contribute the differences 
found in these previous studies, they all contribute knowledge which may help explain the 
variance found in our own results. For example, a study performed by Medical University of 
Vienna utilized a LS180 colon cancer cell line to verify that anticancer drugs such as paclitaxel 
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and vinblastine are shown to induce a PXR-mediated PGP overexpression. Furthermore, it has 
been shown that PXR activation is associated with the metabolic reduction of cytotoxic agents, 
such as doxorubicin in colon cancer cells (9). This particular study identifies a unique method by 
which resistance to doxorubicin is conferred through PXR, while results from additional studies 
also suggest that BCB1 activation is a fundamental mechanism for acquired drug resistance to 
taxanes, such as paclitaxel in ovarian cancer cells (22). It has also been found that paclitaxel 
resistance in SKOV-3 cells is not achieved through the usual PXR-mediated method but rather 
through a novel caspase-3 and caspase-9 independent pathway (20). While not a definitive 
answer, it does set a precedent that paclitaxel resistance can be achieved in numerous cell types 
through methods which have the potential to be unique to each cell type being studied.  
In conclusion, the experiments carried out with this ovarian cancer cell line did not 
confirm the hypothesis that SKOV-3 cells treated with PGP substrates fexofenadine and 
vinblastine could induce ABCB1 gene expression. If further testing were to occur on this project, 
then the addition of cells with confirmed PGP induction would be added for a strong positive 
control for both aims. Additionally, running a drug dosage curve at the start of the project with 
higher concentrations may help ensure that any changes seen in ABCB1 expression within the 
cells are actually due to drug exposure rather than other external factors. Finally, it could be 
beneficial to run qRT-PCR at multiple points throughout the study, rather than all at once at the 
end. This would better qualify the results of the paclitaxel exposure experiment as the test for 
resistance would avoid the possible long-term effects of the drugs and for sure utilize cells which 
exhibit verified ABCB1 induction.  
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Appendix: Linear Regression Coefficients Analysis 
 
Fexofenadine Coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 6.385 .418  15.266 .000 5.224 7.546 
Time -.032 .025 -.535 -1.267 .274 -.103 .038 
a. Dependent Variable: Fex Study 1 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 5.331 .255  20.893 .000 4.623 6.040 
Time -.009 .011 -.366 -.787 .475 -.039 .022 
a. Dependent Variable: Fex Study 2 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 8.034 .129  62.296 .000 7.676 8.392 
Time -.041 .006 -.966 -7.471 .002 -.057 -.026 
a. Dependent Variable: Fex Study 3 
 
 
DMSO Control Coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 5.444 .625  8.705 .001 3.708 7.180 
Time -.010 .040 -.126 -.254 .812 -.122 .102 
a. Dependent Variable: DMSO Study 1 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 5.238 .342  15.300 .000 4.287 6.188 
Time -.021 .015 -.578 -1.417 .230 -.062 .020 
a. Dependent Variable: DMSO Study 2 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 7.652 .258  29.713 .000 6.937 8.367 
Time -.047 .011 -.906 -4.275 .013 -.078 -.017 
a. Dependent Variable: DMSO Study 3 
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Vinblastine Coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 6.462 .454  14.219 .001 5.015 7.908 
Time .076 .040 .743 1.920 .151 -.050 .202 
a. Dependent Variable: Vin Study 1 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 5.646 .291  19.429 .000 4.839 6.453 
Time -.066 .013 -.934 -5.250 .006 -.101 -.031 
a. Dependent Variable: Vin Study 2 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 (Constant) 8.512 .413  20.600 .000 7.365 9.660 
Time -.019 .018 -.472 -1.071 .345 -.068 .030 
a. Dependent Variable: Vin Study 3 
 
 
